首页> 外文期刊>The New England journal of medicine >Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group (see comments) (published erratum appears in N Engl J Med 1998 Jul 2;339(1):59)
【24h】

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group (see comments) (published erratum appears in N Engl J Med 1998 Jul 2;339(1):59)

机译:口服西地那非治疗勃起功能障碍。西地那非研究小组(查看评论)(发表的勘误出现在N Engl J Med 1998年7月2日; 339(1):59)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Sildenafil is a potent inhibitor of cyclic guanosine monophosphate hydrolysis [corrected] in the corpus cavernosum and therefore increases the penile response to sexual stimulation. We evaluated the efficacy and safety of sildenafil, administered as needed in two sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, and mixed causes. METHODS: In a 24-week dose-response study, 532 men were treated with oral sildenafil (25, 50, or 100 mg) or placebo. In a 12-week, flexible dose-escalation study, 329 different men were treated with sildenafil or placebo, with dose escalation to 100 mg based on efficacy and tolerance. After this dose-escalation study, 225 of the 329 men entered a 32-week, open-label extension study. We assessed efficacy according to the International Index of Erectile Function, a patient log, and a global-efficacy question. RESULTS: In the dose-response study, increasing doses of sildenafil were associated with improved erectile function (P values for increases in scores for questions about achieving and maintaining erections were <0.001). For the men receiving 100 mg of sildenafil, the mean score for the question about achieving erections was 100 percent higher after treatment than at base line (4.0 vs. 2.0 of a possible score of 5). In the last four weeks of treatment in the dose-escalation study, 69 percent of all attempts at sexual intercourse were successful for the men receiving sildenafil, as compared with 22 percent for those receiving placebo (P<0.001). The mean numbers of successful attempts per month were 5.9 for the men receiving sildenafil and 1.5 for those receiving placebo (P<0.001). Headache, flushing, and dyspepsia were the most common adverse effects in the dose-escalation study, occurring in 6 percent to 18 percent of the men. Ninety-two percent of the men completed the 32-week extension study. CONCLUSIONS: Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.
机译:背景:西地那非是海绵体中环状鸟苷单磷酸水解的有效抑制剂(已校正),因此增加了对性刺激的阴茎反应。我们评估了西地那非的有效性和安全性,这是对患有器质性,精神性和混合性原因的勃起功能障碍的男性进行的两项连续双盲研究中根据需要施用的。方法:在一项为期24周的剂量反应研究中,532名男性接受口服西地那非(25、50或100 mg)或安慰剂治疗。在为期12周的灵活剂量递增研究中,对329名不同的男性接受西地那非或安慰剂治疗,根据疗效和耐受性,剂量递增至100 mg。这项剂量递增研究之后,在329名男性中,有225名进入了为期32周的开放标签延伸研究。我们根据国际勃起功能指数,患者记录和整体疗效问题评估了疗效。结果:在剂量反应研究中,西地那非剂量的增加与勃起功能的改善有关(关于达到和维持勃起问题的分数增加的P值<0.001)。对于接受西地那非100 mg的男性,治疗后勃起问题的平均得分比基线水平高100%(4.0分对5分的2.0分)。在剂量递增研究的最后四个星期中,接受西地那非的男性在所有性交尝试中成功的比例为69%,而接受安慰剂的男性为22%(P <0.001)。接受西地那非的男性每月平均成功尝试次数为5.9,接受安慰剂的男性平均每月成功尝试次数为1.5(P <0.001)。头痛,潮红和消化不良是剂量递增研究中最常见的不良反应,在6%至18%的男性中发生。百分之九十二的男性完成了为期32周的延伸研究。结论:口服西地那非对勃起功能障碍的男性患者有效,耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号